Langerhans cell histiocytosis: clinical experience with 124 patients.
We cared for 124 pediatric patients with a histologic diagnosis of Langerhans' cell histiocytosis (histiocytosis X) over a period of 14 years. Clinical, laboratory, and radiographic findings were analyzed. The most frequent manifestations were bone lesions, lymph node involvement, and skin infiltration. Liver disease was noted in 50% of patients and lung disease in 23%; hematologic changes were also frequent. Dysfunction and involvement of these three organ systems, plus age of onset, distinguished the group of patients with the highest mortality. All patients with generalized disease or organ dysfunction were treated with systemic chemotherapy. The actuarial survival curve at 10 years was 63%.
Rivera-Luna
R
R
Department of Oncology, National Institute of Pediatrics, Mexico City, Mexico.
Martinez-Guerra
G
G
Altamirano-Alvarez
E
E
Martinez-Avalos
A
A
Cardenas-Cardoz
R
R
Ayon-Cardenas
A
A
Ruiz-Maldonado
R
R
Lopez-Corella
E
E
D000293:Adolescent; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008800:Mexico; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D012871:Skin Diseases / Q000188:drug therapy / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone